Euro vs US Dollar

Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

Registrieren

GRF Eagle Capital Growth Fund Inc

9,4456

0,00 (0,00%)

08 Mai 2024 - Geschlossen

Verzögert um 15 Minuten

Form NPORT-P - Monthly Portfolio Investments Report on Form N-PORT (Public)

Eagle Capital Growth (AMEX:GRF)
Historical Stock Chart
Von Apr 2024 bis Mai 2024

Click Here for more Eagle Capital Growth Charts.

Eagle Capital Growth (AMEX:GRF)
Historical Stock Chart
Von Mai 2023 bis Mai 2024

Click Here for more Eagle Capital Growth Charts.

News Eagle Capital Growth Fund Inc

Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C.
Donnerstag 18 April 2024 (3 Wochen vor) • GlobeNewswire Inc.

Grifols Procleix ArboPlex Assay® Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus Screening
Donnerstag 4 April 2024 (1 Monat vor) • GlobeNewswire Inc.

Form DEF 14A - Other definitive proxy statements
Donnerstag 7 März 2024 (2 Monate vor) • Edgar (US Regulatory)

Form N-CSR - Certified Shareholder Report
Mittwoch 6 März 2024 (2 Monate vor) • Edgar (US Regulatory)

Form NPORT-P - Monthly Portfolio Investments Report on Form N-PORT (Public)
Mittwoch 28 Februar 2024 (2 Monate vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Freitag 23 Februar 2024 (2 Monate vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Freitag 23 Februar 2024 (2 Monate vor) • Edgar (US Regulatory)

Grifols announces positive topline phase 3 fibrinogen clinical trial results
Mittwoch 14 Februar 2024 (3 Monate vor) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Dienstag 13 Februar 2024 (3 Monate vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Dienstag 13 Februar 2024 (3 Monate vor) • Edgar (US Regulatory)

Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-in-Human Subcutaneous Dosing Option for Patients with Alpha1-Antitrypsin Deficiency
Mittwoch 15 November 2023 (6 Monate vor) • GlobeNewswire Inc.

Form NPORT-P - Monthly Portfolio Investments Report on Form N-PORT (Public)
Dienstag 7 November 2023 (6 Monate vor) • Edgar (US Regulatory)

Weitere Eagle Capital Growth Fund Inc News-Artikel

Deutsche Telekom

Euro vs Sterling

Deutsche Lufthansa

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen